Latest news from Cancer Research Institute and RevImmune on Newswise en-us Copyright 2024 Newswise 115 31 / /images/newswise-logo-rss.gif /articles/cancer-research-institute-and-revimmune-announce-dosing-of-first-patient-in-new-phase-2-study-assessing-therapeutic-benefit-of-interleukin-7-in-patients-with-cancer-and-covid-19/?sc=rsin /articles/cancer-research-institute-and-revimmune-announce-dosing-of-first-patient-in-new-phase-2-study-assessing-therapeutic-benefit-of-interleukin-7-in-patients-with-cancer-and-covid-19/?sc=rsin Tue, 30 Mar 2021 07:00:56 EST New immunotherapy approach to treating cancer patients with COVID-19 aims to reduce risk of severe COVID-19 symptoms by reinvigorating patients' cellular immune responses Cancer Research Institute and RevImmune